Ionis Pharmaceuticals to Host Webcast on Q4 Financial Results and RNA Innovations

Ionis Pharmaceuticals Prepares for Financial Results Webcast, Showcasing RNA-targeted Innovations

Ionis Pharmaceuticals, Inc., a trailblazer in RNA-targeted medicines, announces a live webcast on February 19th at 11:30 a.m. Eastern Time to discuss its financial results for the fourth quarter and full year of 2024. This session marks an important occasion for the company, reflecting its commitment to transparency and stakeholder engagement. The webcast will be accessible via the company’s investor relations website, with a replay available for a limited time, ensuring that investors and interested parties can stay informed about the company’s performance and future direction.

With over three decades of expertise, Ionis Pharmaceuticals stands out in the biopharmaceutical field, currently offering six marketed medicines and a promising pipeline filled with late- and mid-stage candidates. These candidates primarily target neurological disorders, cardiovascular diseases, and rare conditions, underlining the company’s dedication to addressing serious health challenges. Ionis’s innovative approach to RNA therapies not only positions it as a leader in the industry but also emphasizes its focus on the biology of diseases, which is critical for developing effective treatments.

The company's recent advancements extend into gene editing, showcasing Ionis’s commitment to exploring new therapeutic methodologies. This innovative spirit, combined with a deep understanding of disease biology, allows Ionis to create meaningful advancements in patient care. As the company prepares to share its financial insights, it also highlights the importance of its ongoing research efforts and the potential impact of its therapies on improving patient outcomes.

In addition to the webcast, Ionis Pharmaceuticals continues to engage with the public through its official website and social media platforms, including X (Twitter) and LinkedIn. This outreach not only keeps stakeholders informed but also reinforces the company’s mission to lead in the development of RNA-targeted medicines. The upcoming financial discussion serves as a critical touchpoint for investors and the broader community to assess the company’s progress and future endeavors in the ever-evolving pharmaceutical landscape.